Episode 69: The future of AbbVieGan, the dogma of amyloid, & some questionable biotech marketing

Published: June 27, 2019, 8:50 p.m.

Can Botox make Big Pharma attractive? What qualifies as a "cabal"? And will the CRISPR patent fight outlive us all?